eGFP antibody (Enhanced Green Fluorescent Protein) Primary Antibody
- Target See all eGFP products
- Antibody Type
- Recombinant Antibody
- Aequorea victoria
- This eGFP antibody is un-conjugated
- Immunocytochemistry (ICC), Immunoprecipitation (IP), ELISA
- Recognizes EGFP, Enhanced Cyan Fluorescent Protein (ECFP) and Enhanced Yellow Fluorescent Protein (EYFP).
- Purified from HEK 293 cell culture supernatant.
- >95 % (SDS-PAGE)
- Enhanced Green Fluorescent Proteins (EGFP).
- Application Notes
- Optimal working dilution should be determined by the investigator.
anti-EGFP, monoclonal antibody (recombinant) (G3) is composed of human variable regions (VH and VL) (lambda-chain) of immunoglobulin fused to the human lgG2 Fc domain.
- For Research Use only
- Lot specific
- In PBS containing 10 % glycerol and 0.02 % sodium azide.
- Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 4 °C,-20 °C
- Storage Comment
Short Term Storage: +4°C
Long Term Storage: -20°C
Stable for at least 1 month after receipt when stored at +4°C. Stable for at least 1 year after receipt when stored at -20°C.
- Expiry Date
- 12 months
Fully in vitro selection of recombinant antibodies." in: Biotechnology journal, Vol. 4, Issue 1, pp. 38-43, (2009) (PubMed).
- Fully in vitro selection of recombinant antibodies." in: Biotechnology journal, Vol. 4, Issue 1, pp. 38-43, (2009) (PubMed).
- Alternative Name
- EGFP (eGFP Products)
- Anti-EGFP, monoclonal antibody (recombinant) (G3) is an antibody developed by antibody phage display technology using a human naive antibody gene library. These libraries consist of scFv (single chain fragment variable) composed of VH (variable domain of the human immunoglobulin heavy chain) and VL (variable domain of the human immunoglobulin light chain) connected by a polypeptide linker. The antibody fragments are displayed on the surface of filamentous bacteriophage (M13). This scFv was selected by affinity selection on antigen in a process termed panning. Multiple rounds of panning are performed to enrich for antigen-specific scFv-phage. Monoclonal antibodies are subsequently identified by screening after each round of selection. The selected monoclonal scFv is cloned into an appropriate vector containing a Fc portion of interest and then produced in mammalian cells to generate an IgG like scFv-Fc fusion protein.